← Leaderboards
Gad Asher Marshall
Massachusetts General Hospital
$11,958,327
Attributed
$15,198,559
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,198,559 · 8
By mechanism
R01$10,854,607 · 3
R42$2,826,862 · 1
R21$790,317 · 2
K23$726,682 · 1
M01$91 · 1
Top collaborators
- Shalendar Bhasin4 shared
- Shahar Arzy2 shared
- Eric Leven Eric Leven Eric Leven2 shared
- Alice D Lam2 shared
- Hugo Spiers2 shared
- Daniel J. Tatar1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Jing Zhou$20,912,829
- Oksana Berezovska$14,319,485
- Mingming Ning$8,518,949
- Sekar Kathiresan$50,580,753
- Herminia D Rosas$18,624,312
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseClinical TrialsCognitiveInstrumental Activity Of Daily LivingCognitionBiological MarkersImpairmentMild Cognitive ImpairmentPositron-Emission TomographyAmyloidSymptomsS Disease PathologyAmnestic Mild Cognitive ImpairmentDementiaBrainPre-ClinicalParticipantImageParietalPittsburgh Compound-BImpaired CognitionMagnetic Resonance ImagingIn Vivo
Grant awards (28)
Neural Correlates of Apathy Across the Alzheimer's Disease Continuum$556,665
R01 · FY2025 · AG · contact PI
The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD$1,000,000
R42 · FY2024 · AG
Neural Correlates of Apathy Across the Alzheimer's Disease Continuum$574,096
R01 · FY2024 · AG · contact PI
A Proof of Concept Trial of a Sirtuin-NAD+ Activator in Alzheimer's Disease$229,495
R01 · FY2024 · AG
The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD$1,500,000
R42 · FY2023 · AG
A Proof of Concept Trial of a Sirtuin-NAD+ Activator in Alzheimer's Disease$881,647
R01 · FY2023 · AG
Neural Correlates of Apathy Across the Alzheimer's Disease Continuum$834,296
R01 · FY2023 · AG · contact PI
Novel automated performance-based ADL outcomes for early AD clinical trials$641,780
R01 · FY2023 · AG · contact PI
A Proof of Concept Trial of a Sirtuin-NAD+ Activator in Alzheimer's Disease$873,053
R01 · FY2022 · AG
Social spatial navigation assessment for early-stage Alzheimer's disease$190,839
R21 · FY2022 · AG · contact PI
Novel automated performance-based ADL outcomes for early AD clinical trials$968,003
R01 · FY2021 · AG · contact PI
Neural Correlates of Apathy Across the Alzheimer's Disease Continuum$836,968
R01 · FY2021 · AG · contact PI
A Proof of Concept Trial of a Sirtuin-NAD+ Activator in Alzheimer's Disease$752,126
R01 · FY2021 · AG
Social spatial navigation assessment for early-stage Alzheimer's disease$190,054
R21 · FY2021 · AG · contact PI
Novel automated performance-based ADL outcomes for early AD clinical trials$835,178
R01 · FY2020 · AG · contact PI
Neural Correlates of Apathy Across the Alzheimer's Disease Continuum$827,561
R01 · FY2020 · AG · contact PI
The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD$326,862
R42 · FY2020 · AG
Novel automated performance-based ADL outcomes for early AD clinical trials$312,440
R01 · FY2020 · AG · contact PI
Investigation of silent mesial temporal lobe hyperexcitability in Alzheimer's disease$183,712
R21 · FY2020 · AG
Novel automated performance-based ADL outcomes for early AD clinical trials$848,052
R01 · FY2019 · AG · contact PI
Investigation of silent mesial temporal lobe hyperexcitability in Alzheimer's disease$225,712
R21 · FY2019 · AG
Novel automated performance-based ADL outcomes for early AD clinical trials$883,247
R01 · FY2018 · AG · contact PI
PIB binding, hypometabolism, apathy and executive dysfunction in MCI and AD$141,558
K23 · FY2013 · AG · contact PI
PIB binding, hypometabolism, apathy and executive dysfunction in MCI and AD$143,595
K23 · FY2012 · AG · contact PI
PIB binding, hypometabolism, apathy and executive dysfunction in MCI and AD$145,983
K23 · FY2011 · AG · contact PI
PIB binding, hypometabolism, apathy and executive dysfunction in MCI and AD$148,044
K23 · FY2010 · AG · contact PI
PIB binding, hypometabolism, apathy and executive dysfunction in MCI and AD$147,502
K23 · FY2009 · AG · contact PI
THE EFFECTS OF DHA IN SLOWING THE PROGRESSION OF ALZHEIMER'S DISEASE$91
M01 · FY2008 · RR · contact PI